Biotech Values

[mcbio]

KALV -

KalVista has developed a proprietary portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company’s portfolio of orally delivered plasma kallikrein inhibitors for HAE is expected to commence Phase 1 clinical trials in the third quarter of 2016. KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor for DME, has successfully completed Phase 1 clinical trials in DME patients…

Can't say I'm entirely current on HAE treatment landscape. I know Shire acquired Dyax in early 2016 for what I think was a subQ HAE drug (http://www.prnewswire.com/news-releases/shire-completes-acquisition-of-dyax-566189981.html ). Do you, or others, know if there is a significant unmet need here for an oral HAE drug (what KALV is focused on) versus what I think are existing subQ/IV options? I.e., is there a legit potential to improve upon efficacy and safety of existing HAE drugs or is the development of an oral treatment likely to only offer incremental improvement and really just be more of a convenience advantage at best?